Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer

(2017) Emil Christensen et al.   EUROPEAN UROLOGY

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs

(2017) Yan-juan Zhu et al.   Oncotarget

Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer

(2017) Rodrigo Goncalves et al.   Journal of the National Comprehensive Cancer Network

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases

(2016) Jing Zhao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

(2016) J. C. Thompson et al.   CLINICAL CANCER RESEARCH

Comparison of liquid-based preparation and conventional smear of fine-needle aspiration cytology of lymph node

(2016) Pranab Dey et al.   Journal of Cytology

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

(2016) Qing Zhou et al.   Journal of Hematology & Oncology

147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study

(2016) E. Arriola et al.   Journal of Thoracic Oncology

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

(2016) Yang-Si Li et al.   Journal of Thoracic Oncology

Scientific Advances in Lung Cancer 2015

(2016) Anne S. Tsao et al.   Journal of Thoracic Oncology

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

(2016) Karen L. Reckamp et al.   Journal of Thoracic Oncology

Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations

(2016) Hua-Jie Dong et al.   LUNG CANCER

The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis

(2016) Tao Jiang et al.   LUNG CANCER

Integrated digital error suppression for improved detection of circulating tumor DNA

(2016) Aaron M Newman et al.   NATURE BIOTECHNOLOGY

Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection

(2016) Clara Bayarri-Lara et al.   PLoS One

Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1

(2016) Yoshiro Nakahara et al.   OncoTargets and Therapy

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

(2016) Jacob J. Chabon et al.   Nature Communications

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

(2016) Marzia Del Re et al.   Oncotarget

Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

(2016) Takayuki Takahama et al.   Oncotarget

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

(2016) D. Zheng et al.   Scientific Reports

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

(2015) Wei Sun et al.   Journal of Hematology & Oncology

Lung Cancer Screening, Version 1.2015

(2015) Douglas E. Wood et al.   Journal of the National Comprehensive Cancer Network

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer

(2015) Xiaoxia Chen et al.   Journal of Thoracic Oncology

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

(2015) Niki Karachaliou et al.   JAMA Oncology

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

(2014) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Liquid biopsy: monitoring cancer-genetics in the blood

(2013) Emily Crowley et al.   Nature Reviews Clinical Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan® -MGB probe genotyping method

(2012) PEIJIA LIU et al.   Experimental and Therapeutic Medicine

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

(2011) Youwei Zhang et al.   CANCER LETTERS

Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

(2011) K. Taniguchi et al.   CLINICAL CANCER RESEARCH

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy

(2011) J. A. Shaw et al.   GENOME RESEARCH

Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer

(2011) Rafael Sirera et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Counting absolute numbers of molecules using unique molecular identifiers

(2011) Teemu Kivioja et al.   NATURE METHODS

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

(2010) Ruth E. Board et al.   BREAST CANCER RESEARCH AND TREATMENT

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Mutated K-rasDNA in Urine, Plasma, and Serum of Patients with Colorectal Carcinoma or Adenomatous Polyps

(2009) Ying-Hsiu Su et al.   Annals of the New York Academy of Sciences

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients

(2009) T. K.F. Yung et al.   CLINICAL CANCER RESEARCH

Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis

(2009) Ruifeng Zhang et al.   LUNG CANCER

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE